
Teva antihypertensive generic duo gets FDA thumbs up
pharmafile | November 7, 2016 | News story | Manufacturing and Production, Sales and Marketing | Azor, FDA, Teva, Tribenzor
Teva has received the approval from the US Food and Drug Administration (FDA) for its generic hypertension treatments Tribenzor (olmesartan medoxomil, amlodipine and hydrochlorothiazide) and Azor (amlodipine and olmesartan medoxomil).
The Israeli company’s Azor generic has already launched in the US, while the Tribenzor generic has entered final pre-launch stages.
The Tribenzor generic tablets are a combination of an angiotensin II receptor blocker, a dihydropyridine calcium channel blocker and a thiazide diuretic indicated for the treatment of hypertension, to lower blood pressure. The original drug generated sales of $240 million in the US alone last year.
The Azor generic tablets meanwhile are a dihydropyridine calcium channel blocker and angiotensin II receptor blocker combination product indicated for the treatment of hypertension, alone or with other antihypertensive agents. The original drug chalked up $354.1 million in the US market last year.
High blood pressure can lead to cardiovascular conditions such as strokes and myocardial infarctions, which often prove to be fatal. With these approvals, patients will have access to a wider range of treatments to treat hypertension.
Matt Fellows
Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …





